300158 Shanxi Zhendong Pharmaceutical
- 4.31
- +0.05+1.17%
Shanxi Zhendong Pharmaceutical News
Companies Like Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring reve
Zhendong Pharmaceutical (300158.SZ) has repurchased 2.16% of its shares at a total cost of 103 million yuan
Zhitong Finance App News, Zhendong Pharmaceutical (300158.SZ) announced that the company's repurchase has been completed. As of April 30, 2024, the company had repurchased a total of 22.174,900 shares of the company's shares, accounting for 2.16% of the company's total share capital, and the total transaction amount was 103 million yuan (excluding transaction fees).
Investors in Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) From a Year Ago Are Still Down 26%, Even After 9.5% Gain This Past Week
Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can do both better or worse than that. For example, the Shanxi Zhendong Pharmaceuti
Zhendong Pharmaceutical (300158.SZ) appoints Liu Yongsen as financial director
Zhendong Pharmaceutical (300158.SZ) announced that the company's board of directors recently received the written resignation of Liu Changlu, the company's financial director...
Zhendong Pharmaceutical (300158.SZ): Net profit of 23.1016 million yuan for the first quarter reversed year-on-year losses
Gelonghui, April 22 | Zhendong Pharmaceutical (300158.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 782 million yuan, down 17.79% year on year; net profit attributable to shareholders of listed companies was 23.1016 million yuan, turning a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 8.5924 million yuan; basic earnings per share.
Zhendong Pharmaceutical (300158.SZ) elects director Li Kun as chairman
Zhendong Pharmaceutical (300158.SZ) announced that the company's board of directors recently received a written resignation report from the company's chairman Li Anping...
Zhendong Pharmaceutical (300158.SZ) has spent 84.251 million yuan to buy back 1.75% of its shares
Zhendong Pharmaceutical (300158.SZ) issued an announcement. As of March 31, 2024, the company has approved share repurchases...
Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Market Cap Dropped CN¥432m Last Week; Retail Investors Bore the Brunt
Key Insights The considerable ownership by retail investors in Shanxi Zhendong PharmaceuticalLtd indicates that they collectively have a greater say in management and business strategy 43% of the bu
Several major problems with equity pledges and capital occupation of Zhendong Pharmaceutical have come to light
“Investor Network” Cai Jun Recently, Zhendong Pharmaceutical (hereinafter referred to as the “Company”, 300158.SZ) announced that shareholders pledged shares, involving both the controlling party and the actual controller. Earlier, the company owned Landy Pharmaceuticals and relied on it to obtain a double harvest of capital and performance. However, since 2022, the company has been in losses, and when to turn losses into profits has become a topic of concern for the market. If you want to make a profit, you need revenue side growth and cost segment control. At the same time, various transactions between the holding party and the company have also received attention from the supervisory authorities. According to the announcement, Zhendong Group, the controlling shareholder of the company, and Li Anping, the actual controller, pledged a total of 305 million shares, accounting for the public
Zhendong Pharmaceutical (300158.SZ): A total cost of 46.72 million yuan to buy back 1.02% of the shares
Gelonghui, Feb. 23 | Zhendong Pharmaceutical (300158.SZ) announced that as of February 21, 2024, the company had repurchased a total of 10,497,004 shares of the company through a special stock repurchase securities account, accounting for 1.02% of the company's total share capital. The highest transaction price was 4.81 yuan/share, the minimum transaction price was 4.31 yuan/share, and the total transaction amount was RMB 46,724,627.55.
Zhendong Pharmaceutical (300158.SZ): Initial repurchase of 8.6463 million shares involving 38.675 million yuan
Gelonghui, Feb. 7, Zhendong Pharmaceutical (300158.SZ) announced that on February 7, 2024, for the first time, the company repurchased 86463.04 million shares through a special stock repurchase securities account, accounting for 0.84% of the company's total share capital. The highest transaction price was 4.54 yuan/share, the lowest transaction price was 4.31 yuan/share, and the total transaction amount was RMB 38.27,500 (not including transaction fees).
Revenues Working Against Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Share Price Following 26% Dive
Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month. Instead of being re
Zhendong Pharmaceutical (300158.SZ) announced a net loss of 30 million to 40 million yuan in 2023, which narrowed 22% to 42% year-on-year
Zhendong Pharmaceutical (300158.SZ) disclosed its 2023 annual results forecast. The company expects the reporting period to be listed...
Zhendong Pharmaceutical (300158.SZ): To invest in Longchuangji Pharmaceutical, it will hold 60% of its shares
Gelonghui, January 19, 丨 Zhendong Pharmaceutical (300158.SZ) announced that in order to lay out the vaginal probiotics field, enrich the company's product pipeline, and enhance the company's profitability, the company signed an “Investment Agreement on Guangdong Longchuangji Pharmaceutical Co., Ltd.” (hereinafter referred to as the “Investment Agreement”) and “Equity Transfer Agreement for Guangdong Longchuangji Pharmaceutical Co., Ltd.” (hereinafter referred to as the “Equity Transfer Agreement”) with Guangdong Longchuangji Pharmaceutical Co., Ltd. (hereinafter referred to as the “Equity Transfer Agreement”) on January 19, 2024 The main content of the investment agreement is: the company to Longchuangji Pharmaceutical increased its capital by 3,0
While Shareholders of Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate
Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) shareholders have seen the share price descend 16% over the month. But that doesn't change the fact that the returns over the last five years ha
Zhendong Pharmaceutical (300158.SZ): The company has not actually invested in Aloe Vera Qingwang and no longer holds its shares
Glonghui December 20 | Zhendong Pharmaceutical (300158.SZ) stated on the investor interactive platform on December 20 that the company has not actually invested in Aloe Vera Qingwang and no longer holds its shares.
Zhendong Pharmaceutical (300158.SZ): Phase III Employee Stock Ownership Plan Completes Stock Purchase
Gelonghui Pharmaceutical (300158.SZ) announced on December 4|Zhendong Pharmaceutical (300158.SZ) announced that as of the disclosure date of this announcement, the company's third phase of the employee stock ownership plan had purchased a total of 38,967,619 shares through centralized bidding transactions through the secondary market, accounting for 3.7925% of the company's total share capital. The total transaction amount was 244,032,009.55 yuan, and the average transaction price was about 6.2624 yuan/share.
Calculating The Intrinsic Value Of Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158)
Key Insights Shanxi Zhendong PharmaceuticalLtd's estimated fair value is CN¥7.30 based on 2 Stage Free Cash Flow to Equity Shanxi Zhendong PharmaceuticalLtd's CN¥7.06 share price indicates it is tra
Zhendong Pharmaceutical (300158.SZ): The third phase of the employee stock ownership plan purchased a total of 2.61% of shares
Gelonghui Pharmaceutical (300158.SZ) announced on November 15, Zhendong Pharmaceutical (300158.SZ) announced that as of the disclosure date of this announcement, the third phase of the company's employee stock ownership plan has purchased a total of 26,768,900 shares of the company's shares through centralized bidding transactions through the secondary market, accounting for 2.6053% of the company's total share capital. The total transaction amount is 156,515,326 yuan, and the average transaction price is about 5.85 yuan/share.
Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Last Week's 8.3% Decline Must Have Disappointed Retail Investors Who Have a Significant Stake
Key Insights The considerable ownership by retail investors in Shanxi Zhendong PharmaceuticalLtd indicates that they collectively have a greater say in management and business strategy A total of 25
Analysis
Price Target
No Data
